



Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Feb 25, 2025

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn[®] Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control[®] platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

B. Riley Securities Precision Oncology and Radiopharma Conference

- Synthetic Lethality Panel: Friday, February 28, 2025, at 9 a.m. EST in New York, NY
- Presenter: Adrian Gottschalk, President and Chief Executive Officer

TD Cowen 45th Annual Health Care Conference

- Presentation: Monday, March 3, 2025, at 2:30 p.m. EST in Boston, MA
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in virtual one-on-one meetings on Monday, March 3, 2025

A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website, www.foghorntx.com, and will be available for 90 days.

About Foghorn Therapeutics

Foghorn[®] Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control[®] platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com